Deal overview
| Target | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (RIGHTS TO HRS-9821) |
|---|---|
| Bidder | GSK PLC |
| Price | £50.00 Full version or £25.00 Light version |
| Publication Date | Jul 28, 2025 |
| Abstract | On 28 July 2025, the quoted UK-based pharmaceutical group GSK plc ("GSK") announced that it had entered into agreements with its quoted Chinese peer Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui") to develop up to 12 medicines across respiratory, immunology and inflammation, and oncology. The agreements included: * an exclusive worldwide licence (excluding mainland ... |
| Number of pages (Full version) | 5 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
